Pfizer, Moderna Jump After FDA Clears Covid Booster Shot For Adults | ZeroHedge
Francesco Abbruzzino, The Uncensored Report, LLC
Update (830am ET): Pfizer has joined Modern in trading sharply higher – and hitting new record highs – when moments after the Moderna announcement, Pfizer and BioNTech also said the U.S. Food and Drug Administration has expanded the emergency use authorization of a booster dose of the Pfizer-BioNTech COVID-19 vaccine to include individuals 18 years of age and older. The booster dose is to be administered at least six months after completion of the primary series, and is the same dosage strength as the doses in the primary series.
Outright bans across numerous (mostly Nordic) countries due to widespread reports it is causing myocarditis in children and adults? No problem: moments ago the FDA cleared Moderna’s Covid-19 booster shot for all Americans 18 and older, making millions more people eligible for extra protection as concern about a potential winter wave of infections grows. As to whether those millions will take the booster shot knowing that the “vaccine” doesn’t actually prevent them from catching covid, and at best mitigates the severity of the disease even as it creates risks of other, just as unpleasant side-effects, is unclear.
JUST IN – FDA approves Pfizer and Moderna vaccine booster shots under Emergency Use Authorization for all adults in the U.S.
— Disclose.tv (@disclosetv) November 19, 2021
The U.S. Food and Drug Administration said adults who received their second dose of the company’s shot at least six months ago are now eligible to receive a third, according to a statement Friday from Moderna. The booster from Pfizer Inc. and BioNTech SE is expected to gain a similar clearance on Friday.